Showing a cardiovascular benefit would have been icing on the cake for Novo Nordisk’s oral GLP-1 agonist, but the data still look strong enough to support blockbuster…
BTG’s string-of-beads tempts Boston Scientific to shell out £3.3bn ($4.2bn) for the UK company.
Mainstay Medical still hopes for US approval of its Reactiv8 device for chronic back pain despite trial failure.
In the seven months since its founding the company has attracted $793m of financing. Now it must execute.
Long-awaited final readout of the Mystic study draws a blank, and future biomarker analyses will cut little ice with investors who have already declared Keytruda the…
Padua gambit seems to have worked as new gene therapy looks the equal of Pfizer/Spark Therapeutics.
The phase III failure of one of Bone Therapeutics’ cell therapies puts its other one under greater pressure than ever.
After failing in retinal vein occlusion, the prospects for the eye project Xipere – and Clearside Biomedical itself – hinge on the smaller uveitis indication.
A partial interim trial success could give GKT831 a new lease of life in liver diseases but full data, due next year, will be watched closely.